Feb 10,2021

Children’s Community Health Plan Offers Freespira´s digital therapeutic treatment for panic attacks, panic disorder, and PTSD

Children’s Community Health Plan (CCHP) has partnered with Freespira, Inc., the maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder and post-traumatic stress disorder. CCHP, an affiliate of Children’s Wisconsin, is an HMO dedicated to providing access to the highest quality health care and services to members living in Wisconsin. Freespira is now available to all of CCHP’s members, including Medicaid patients, making it the first health plan to offer this new digital treatment in Wisconsin.

COLLABORATION PARTNERSHIP

#insurance

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 17,2021

Pear Announces Indiana Family and Social Services Administration Division of Mental Health and Addiction will Provide Access to PDTs

Pear Therapeutics, Inc. announced today that the Indiana Family and Social Services Administration’s Division of Mental Health and Addiction (DMHA) is providing access to Pear’s FDA-authorized prescription digital therapeutics (PDTs) reSET® and reSET-O® for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively. Patients will be prescribed and treated with reSET or reSET-O. Funding is provided by the State Opioid Response grant, administered by DMHA, and part of the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA) State Opioid Response (SOR) grant program for people in need of prevention, treatment and recovery support for opioid use disorder.

PRODUCT

#pdt

View Analyst & Ambassador Comments
Go to original news
Feb 26,2021

Boehringer Ingelheim and Click Therapeutics talk about what makes DTx and pharma partnerships tick

Yesterday, at DTx West, representatives from Click Therapeutics and Boehringer Ingelheim sat down to talk about the what and why of pharma DTx partnerships. In September, the company signed a $500 million plus digital deal with Boehringer Ingelheim to develop and commercialize a digital therapeutic.

View Analyst & Ambassador Comments
Go to original news
Feb 24,2021

Otsuka and Click Therapeutics Initiate First-of-its-Kind Fully Remote Clinical Trial Using Digital Therapeutics as Adjunctive Therapy in Adults With Major Depressive Disorder

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Click Therapeutics, Inc. announce the initiation of the Mirai study, a landmark fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD) who are on antidepressant monotherapy. The pivotal, randomized, controlled trial will enroll up to 540 patients nationwide. Trial participation will be 10 weeks and efficacy will be evaluated as a change from baseline in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score. Otsuka and Click will collaborate with Verily, a subsidiary of Alphabet, to execute the trial as a fully remote trial.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 03,2021

Freespira Now Available to Adolescents for Panic Attacks, Panic Disorder and PTSD

Freespira, the only FDA-cleared digital therapeutic proven to significantly reduce or eliminate panic attacks and PTSD symptoms in just 28 days, is now available to adolescents. As an alternative to medications and talk therapy, Freespira is unique in its approach to addressing the underlying causes of panic disorder and PTSD symptoms by addressing physiological causes of hypersensitivity to carbon dioxide and related breathing irregularities.

PRODUCT

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 24,2021

Mental health chatbot Woebot could be adapted to tackle substance use

A recent study published in the Journal of Medical Internet Research (JMIR) shows initial support for a new version of Woebot – a text-based chatbot app designed to address mental health issues – that is designed to reduce substance use and other measures tied to substance use disorder (SUD). Conducted by researchers from Stanford University School of Medicine and Woebot Health, the investigation found that 101 participants in the eight-week program reported reduced cravings and increased confidence in their ability to resist urges – among other encouraging outcomes.

CLINICAL STUDY

#mobile app

#cbt

#chatbot

View Analyst & Ambassador Comments
Go to original news
Mar 24,2021

How does gamification work in therapy?

With gamification in the form of digital therapy playing an increasing role in treatments – including the treatment of issues in children such as learning disorders – it’s good to have an understanding of what gamification encompasses and how it works in a clinical setting.

View Analyst & Ambassador Comments
Go to original news
Apr 02,2021

Do AI therapy chatbots work? Sometimes better than a therapist, says Woebot CEO Michael Evers

It’s no secret that the state of mental health across the country is worse than ever, mainly due to the effects of the pandemic. As more and more people search for access to therapy, a new class of startups has grown in popularity: AI therapy platforms. One of those platforms, Woebot Health, created an AI chatbot that listens to users and guides them through clinically validated treatment. Woebot’s current CEO, Michael Evers, never even worked out of the company’s San Francisco offices — he started right after the pandemic hit. Despite that, he saw something special in the startup.

PRODUCT

#chatbot

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 28,2021

82 Percent of Employees with Panic Attacks Find Relief With Digital Therapeutic

Freespira, Inc., the maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder (PD) and post-traumatic stress disorder (PTSD) in only 28 days, today announced that the Journal of Mental Health and Clinical Psychology published data demonstrating that PD severity can be significantly reduced with its first-of-its-kind treatment. Crossover Health conducted the study with eligible employees at its Midtown, New York City health center.

CLINICAL STUDY

#telehealth

#coaching

View Analyst & Ambassador Comments
Go to original news
Jun 15,2021

Freespira Wins Juniper Research Future Digital Health Innovation Award for Best Mental Health Therapeutic Solution

Freespira, Inc., the maker of the first FDA-cleared digital therapeutic proven to significantly reduce or eliminate symptoms of panic attacks, panic disorder (PD) and post-traumatic stress disorder (PTSD), in just 28-days, today announced that the company has received Juniper Research’s Future Digital Health Innovation Award for Best Mental Health Therapeutic Solution at the Platinum level.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH